Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NU1025 (NSC-696807) 是一种PARP 的有效抑制剂,IC50为 400 nM,Ki 为 48 nM。它可增强电离辐射和抗癌药物的细胞毒性,有抗癌和神经保护的作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 215 | 现货 | ||
2 mg | ¥ 297 | 现货 | ||
5 mg | ¥ 547 | 现货 | ||
10 mg | ¥ 970 | 现货 | ||
25 mg | ¥ 1,880 | 现货 | ||
50 mg | ¥ 3,250 | 现货 | ||
100 mg | ¥ 4,750 | 现货 | ||
500 mg | ¥ 9,870 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 589 | 现货 |
产品描述 | NU1025 (NSC-696807) is a potent PARP inhibitor with IC50 of 400 nM. |
靶点活性 | PARP:400 nM |
体外活性 | NU1025 (0.2 mM) treatment attenuates Water2 induced cytotoxicity. NU1025 per se does not have any effect on cell viability. NU1025 pretreatment significantly increases cell viability (82.59 4.67%) in SIN-1 (0.8 mM) exposed cells.[2] NU1025 has no detectable effect on the proliferation of D54 and U251 cells. Treatment with NU1025 markedly inhibits the enhanced activation of PARP-1 induced by TPT and RT treatment.[3] No DNA strand breakage is detected following exposure to 200 μM NU1025 alone.[4] |
体内活性 | Treatment with NU1025 (1 and 3 mg/kg) reduces the infarction to 25% and 45% versus vehicle treated rats, respectively. NU1025 (1 and 3 mg/kg) treatment significantly reduces edema volume. NU1025 also produces significant improvement in neurological deficits.[2] |
激酶实验 | PARP activation assay: Cells are suspended in hypotonic buffer (9 mM HEPES, pH 7.8, 4.5% (v/v) dextran, 4.5 mM MgCl2 and 5 mM DTT) at 1.5 × 107/mL on ice for 30 min, then 9 vol of isotonic buffer (40 mM HEPES, pH 7.8, 130 mM KCl, 4% (v/v) dextran, 2 mM EGTA, 2.3 mM MgCl2, 225 mM sucrose and 2.5 mM DTT) is added. The reaction is started by adding 300 μL cells to 100 μL 300 μM NAD+ containing [32P]-NAD+, and terminated by the addition of 2 mL ice-cold 10% (w/v) TCA +10% (w/v) sodium pyrophosphate. After 30 min on ice the precipitated 32P-labelled ADP-ribose polymers are filtered, washed five times with 1% (v/v) TCA, 1% (v/v) sodium pyrophosphate, dried and counted. |
细胞实验 | Cells are seeded in 96-well plates at a density of 2,500 cells/well and treated with the indicated doses of NU1025. Adherent cells are irradiated in medium with 250 kVp X-rays (dose rate 0.5 Gy/min). Untreated cells are used as a control. Following an up to 5 day incubation, cell proliferation is assessed by MTT assay.(Only for Reference) |
别名 | NSC 696807 |
分子量 | 176.17 |
分子式 | C9H8N2O2 |
CAS No. | 90417-38-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 17.6 mg/mL (100 mM)
1eq. NaOH: 17.6 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / 1eq. NaOH | 1 mM | 5.6763 mL | 28.3817 mL | 56.7634 mL | 141.9084 mL |
5 mM | 1.1353 mL | 5.6763 mL | 11.3527 mL | 28.3817 mL | |
10 mM | 0.5676 mL | 2.8382 mL | 5.6763 mL | 14.1908 mL | |
20 mM | 0.2838 mL | 1.4191 mL | 2.8382 mL | 7.0954 mL | |
50 mM | 0.1135 mL | 0.5676 mL | 1.1353 mL | 2.8382 mL | |
100 mM | 0.0568 mL | 0.2838 mL | 0.5676 mL | 1.4191 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
NU1025 90417-38-2 Chromatin/Epigenetic DNA Damage/DNA Repair PARP repair anti-cancer cytotoxicity inhibit NU 1025 DNA NSC-696807 NU-1025 Inhibitor PAR Neuroprotective NSC696807 NAD poly ADP ribose polymerase NSC 696807 inhibitor